Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Vitamin C - a new player in regulation of the cancer epigenome

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Multiple endocrine neoplasia type 2: A reveiw

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Over the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their central roles in carcinogenesis. In hematological cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), drugs that reverse epigenetic aberrations are now the standard of care. Recent in vitro studies suggest that vitamin C at physiological concentrations, combined with hypomethylating agents may act synergistically to cause DNA demethylation through active and passive mechanisms, respectively. Additionally, several recent studies have renewed interest in the use of pharmacological doses of vitamin C injected intravenously to selectively kill tumour cells. This review will focus on the potential of vitamin C to optimize the outcome of epigenetic therapy in cancer patients and alternatively to act as a therapeutic at high doses.

OriginalsprogEngelsk
TidsskriftSeminars in Cancer Biology
Sider (fra-til)59-67
ISSN1044-579X
DOI
StatusUdgivet - aug. 2018

ID: 52055993